论文部分内容阅读
目的 :探讨环孢霉素A在高危角膜移植手术后防治角膜移植排斥反应的疗效。方法 :对在我院施行穿透性及板层角膜移植术中属于高危角膜移植的病例共 2 4例 2 6只眼 ,其中≥ 9mm的大植片的有 12只眼 (占 5 0 % ) ,在术后 2 6只眼均用环孢霉素A口服及环孢霉素A液滴眼。结果 :角膜移植术后出现角膜排斥反应的有 10例 11只眼 (占 42 3% ) ,经过治疗后角膜植片均透明 ,术后角膜移植片最终透明者有 2 4只眼 (占 92 3% ) ,未见严重副作用。结论 :证明在高危角膜移植术后应用环孢霉素A治疗角膜移植排斥反应是确实有效。
Objective: To investigate the curative effect of cyclosporin A in the prevention and treatment of corneal graft rejection after high-risk corneal transplantation surgery. Methods: Twenty-four cases (26 eyes) of high-risk corneal transplants in penetrating and lamellar keratoplasty were performed in our hospital. Twelve eyes (50% Cyclosporin A was given orally and cyclosporin A drops in 26 eyes after operation. Results: There were 10 eyes (42.3%) of corneal allograft after keratoplasty. After treatment, the corneal graft was transparent. There were 24 eyes in the final transparent corneal graft (92 3% %), No serious side effects. CONCLUSIONS: It is demonstrated that cyclosporine A is effective in treating corneal graft rejection after high-risk corneal transplantation.